Age Cohorts & Vaccines
The Joint Committee on Vaccination and Immunisation (JCVI) and the Medicines and Healthcare products Regulatory Agency (MHRA) has recommended that under-30s in the UK are offered an alternative Covid vaccine to the AstraZeneca jab.
To ensure age groups within the remainder of the adult population receive the most clinically appropriate vaccines, we will be sending appointment invitations based on our delivery of vaccines from now until the end of July.
This will mean that some people aged 18-29 may be offered vaccination earlier than some older individuals.
To ensure our vaccine supply is administered as quickly as it is received, we will continue to run two streams for those aged 18-49.
One will deliver the Pfizer vaccine to those under the age of 30, and one will deliver the Oxford AstraZeneca vaccine to those aged between 30 and 49.
We are adopting this pragmatic approach to ensure vaccines are not left for long periods unused.
Those aged under 30 who have already received a first dose of the Oxford AstraZeneca vaccine for health reasons will continue to receive a second dose of the same vaccine at the due time, as there have been no serious adverse events attributed to second doses of the Oxford vaccine.
This is all consistent with advice from the Joint Committee on Vaccination and Immunisation (JCVI) and the Medicines and Healthcare products Regulatory Agency (MHRA).
We remain on course to offer vaccination to the remaining adult population well before the Welsh Government’s end of July milestone. Although there is currently some variation in the per cent of people vaccinated in each cohort in different local authority areas, we can see from appointment bookings for the next few weeks that this variation evens out.
This variation is a result of the population size of individual cohorts in each local authority area, the amount and type of vaccine received, and the need to offer an alternative first dose vaccine to the Oxford AstraZeneca vaccine to those aged under 30, in line with guidance from the advice from the Joint Committee on Vaccination and Immunisation (JCVI) and the Medicines and Healthcare products Regulatory Agency (MHRA).